secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2025-09-04T23:59:59+00:00
Accession:  0001001233-25-000006
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo reports positive eGFR slopes in Phase 1/2 STAAR gene therapy for Fabry; BLA planned Q1 2026
--------------------------------------------------------------------------------

- Mean annualized eGFR slope of +1.965 mL/min/1.73m2/yr (95% CI: -0.153, 4.083) at 52 weeks across 32 patients.
- All 18 patients on ERT at baseline safely withdrew; one later resumed per physician's decision.
- 69% of patients improved FOS-MSSI severity score at 12 months; SF-36 QoL scores showed statistically significant gains.
- BLA submission for isaralgagene civaparvovec targeted Q1 2026 under Accelerated Approval pathway, subject to funding.
- Company notes need for substantial additional capital to continue as going concern and advance Fabry program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000100123325000006/0001001233-25-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000100123325000006/sgmo-20250904.htm
  HTML page:      https://secwatch.observer/filing/0001001233-25-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer